Article in Trends in pharmacological sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
3 authors.
Courtney A MillerDepartment of Molecular Medicine, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL 33458, USA; Department of Neuroscience, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL 33458, USA. Electronic address: cmiller@scripps.edu.
Alfredo Quinones-HinojosaDepartment of Neurosurgery, Mayo Clinic, Jacksonville, FL 32224, USA.
Steven S RosenfeldDepartment of Neurology, Mayo Clinic, Jacksonville, FL 32224, USA. Electronic address: rosenfeld.steven@mayo.edu.
Funding
Phase 0/I dose escalation trial of MT-125 monotherapy in recurrent high-grade gliomasR44CA278293 · NCI · MYOSIN THERAPEUTICS INC. · PI Michael J Brownstein · 2025 to 2026
$4.5M
Targeting Kif11 to Treat Glioblastoma Invasion and ProliferationR01NS073610 · NINDS · MAYO CLINIC JACKSONVILLE · PI CANOLL, PETER, ELMQUIST, WILLIAM · 2012 to 2021
$4.3M
Myosin II regulation of actin dynamics and the selective vulnerability of methamphetamine- and opioid-associated memoryR01DA049544 · NIDA · UNIVERSITY OF FLORIDA · PI MILLER, COURTNEY A, RUMBAUGH, GAVIN R · 2020 to 2024
$3.6M
Targeting Go and Grow in GlioblastomaR01NS118513 · NINDS · MAYO CLINIC JACKSONVILLE · PI CANOLL, PETER, KENCHAPPA, RAJAPPA · 2020 to 2024
$2.8M
MT-125 for the Therapeutic Treatment of GlioblastomaR42CA278293 · NCI · MYOSIN THERAPEUTICS INC. · PI ROSENFELD, STEVEN S · 2023 to 2025
$2.7M
Tumor targeted drug delivery nanoplatform to overcome therapy resistance glioblastomaR01NS129671 · NINDS · MAYO CLINIC JACKSONVILLE · PI DEBABRATA MUKHOPADHYAY · 2023 to 2026
$2.4M
Self-Assembling Camptothecin Nanofiber Hydrogels as Adjunct Therapy for Intraoperative Treatment of Malignant GliomaR01CA284268 · NCI · JOHNS HOPKINS UNIVERSITY · PI Kaisorn Lee Chaichana, Honggang Cui · 2023 to 2026
$2.1M
Developing nonmuscle II inhibitors for substance use relapseUH3NS096833 · NINDS · SCRIPPS FLORIDA · PI GRIFFIN, PATRICK ROBERT, KAMENECKA, THEODORE M · 2017 to 2020
$1.8M
A Bioprinted Volumetric Model of Vascularized GlioblastomaR01CA282451 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Kaisorn Lee Chaichana, Y. Shrike Zhang · 2023 to 2026
$1.7M
Generating Synthetic Lethality in Glioblastoma with a First-In-Class Non-Muscle Myosin II InhibitorR01CA295558 · NCI · MAYO CLINIC JACKSONVILLE · PI Peter Canoll, STEVEN S ROSENFELD · 2025 to 2026
$1.2M
Developing nonmuscle myosin II inhibitors for the treatment of glioblastomaR33NS119714 · NINDS · UNIVERSITY OF FLORIDA · PI MILLER, COURTNEY A, ROSENFELD, STEVEN S · 2022 to 2023
$964k
Developing nonmuscle II inhibitors for substance use relapseUH2NS096833 · NINDS · SCRIPPS FLORIDA · PI GRIFFIN, PATRICK ROBERT, KAMENECKA, THEODORE M · 2016 to 2016
Non-muscle myosin II (NMII) comprises a family of cytoplasmic motors with important roles in both normal biology and disease. In this forum article we describe recent developments that validate NMII as a therapeutic target, and we illustrate how this validation can identify novel and translationally viable approaches to treat a variety of diseases.
Indexed as
Myosin Type IIAnimalsHumansMolecular Targeted TherapyMyosin Type IIcancerdiseaseneuroplasticityproliferationsignalingsubstance use disorder
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Non-muscle myosin II is a promising therapeutic target. · full record | OpenQuestion